Finasteride Tablet
Product Images NDC 0615-8562

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 0615-8562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Finasteride Tab 8562 1)

Chemical structure diagram of Finasteride, illustrating its molecular framework with labeled functional groups consistent with this active ingredient.*

FDA Label Image

Figure1 (Finasteride Tab 8562 2)

A line graph titled 'Symptom Score in PLESS' showing mean change from baseline ± 1 SE over four years. Two lines compare symptom scores for Placebo and Finasteride groups, with symptom scores decreasing more over time in the Finasteride group compared to Placebo. Sample sizes at each time point are indicated.*

FDA Label Image

Figure2 (Finasteride Tab 8562 3)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride and placebo groups over 48 months. The X-axis shows observation time in months, and the Y-axis indicates the percent of patients. The chart includes cumulative event counts and patients at risk for both groups at specific intervals.*

FDA Label Image

Figure3 (Finasteride Tab 8562 4)

A line graph showing the percent of patients developing acute urinary retention over 48 months, comparing Finasteride and placebo groups. The x-axis represents observation time in months, and the y-axis shows percent of patients. The graph includes cumulative event numbers and at-risk patients per year for both groups.*

FDA Label Image

Figure4 (Finasteride Tab 8562 5)

A line graph titled 'Prostate Volume in PLESS' showing mean percent change from baseline over four years for two groups: Placebo and Finasteride. The y-axis ranges from -20 to 20 percent change. The Finasteride group shows a decrease in prostate volume over time, while the Placebo group shows an increase. Sample sizes for each group at different time points are listed below the x-axis.*

FDA Label Image

Figure5 (Finasteride Tab 8562 6)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing the percent of events over 5.5 years from randomization. The graph compares treatment groups: Placebo, Finasteride, Doxazosin, and Combination, illustrating differences in cumulative incidence rates over time.*

FDA Label Image

Principal Display Panel (Finasteride Tab 8562 7)

Finasteride Tablets, USP 5 mg prescription drug label from NCS HealthCare of KY, LLC dba Vangard Labs. The label indicates a package quantity of 30 tablets, batch lot number 8562, and includes barcodes. Storage instructions specify controlled room temperature 20° to 25°C and warnings note it should not be used by women or children, especially those who may be pregnant. Manufacturer listed as Dr. Reddy's, packaging by Vangard Labs in Glasgow, KY.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.